Dare Bioscience Inc DARE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Daré Bioscience to Present at Stifel’s 2026 Healthcare Conference
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
Daré Bioscience Addresses New National Focus on Women’s Health in Virtual Investor “What This Means” Discussion
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities
Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
Trading Information
- Previous Close Price
- $0.66
- Day Range
- $0.61–0.68
- 52-Week Range
- $0.61–3.78
- Bid/Ask
- $0.61 / $0.63
- Shares Outstanding
- 19.67M
- Market Cap
- $12.27M
- Volume/Avg
- 146,623 / 503,306
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.84
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 24
Valuation
Metric | DARE |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 6.84 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | DARE |
|---|---|
Quick Ratio | 0.77 |
Current Ratio | 0.99 |
Interest Coverage | — |
Quick Ratio
DARE
Profitability
Metric | DARE |
|---|---|
Return on Assets (Normalized) | −37.52% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,079.10% |
Return on Assets
DARE
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|ff@kN# | LOCK|$^!@ | $139B | |||
| Moderna Inc MRNA | LOCK|!G%Jml | LOCK|dNZ | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|pd<S<@! | LOCK|x<LMl | $96B | |||
| argenx SE ADR ARGX | LOCK|>X@^Cf | LOCK|!$> | $57B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|&G@?<>$ | LOCK|B& | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|rh><@wz | LOCK|#F<D | $30B | |||
| Incyte Corp INCY | LOCK|v$?Sf>& | LOCK|>xb | $25B | |||
| BioNTech SE ADR BNTX | LOCK|<GZh>p& | LOCK|<R< | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|X%%HN!G | LOCK|wYBd! | $22B | |||
| BridgeBio Pharma Inc BBIO | LOCK|&fg>&!D | LOCK|>vx | $15B |
United States